Targeting PKCι-PAK1 in EGFR-mutation Positive Non-small Cell Lung Cancer

Overview

Journal Transl Lung Cancer Res

Date 2019 Nov 19

PMID 31737502

Citations 8

Authors

Masaoki Ito

Carles Codony-Servat

Niki Karachaliou

Rafael Rosell

Affiliations

Soon will be listed here.

Abstract

Background: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) induce significant responses in EGFR-mutation positive non-small cell lung cancer (NSCLC). However, universal progression is observed.

Methods: The effect of the anti-rheumatoid agent, auranofin, a selective inhibitor of oncogenic protein kinase C iota (PKCι) signaling and IPA-3, a non-ATP competitive p21-activated kinase 1 (PAK1) inhibitor in treatment-naïve and EGFR TKI-resistant EGFR-mutation positive NSCLC cell lines was investigated. PC9 and HCC827 cells were used. The four EGFR-TKI resistant cell lines were established from PC9. Cell viability assays, drug combination studies, and western blotting were performed. The combination index, and RTK or non-RTK expression were performed.

Results: The combination of IPA-3 and auranofin was highly synergistic in all 6 cell lines (combination indexes ranged from 0.37-0.62). The activities on EGFR, CDCP1, AXL, MET, and downstream effector pathways, including PAK1, PKCι, ERK, AKT, STAT3, Src, and YAP1 were abrogated.

Conclusions: The combination of auranofin with IPA-3 could be a potential therapy for EGFR-mutation positive NSCLC resistant to EGFR TKIs. Auranofin with IPA-3 could become a therapeutic solution for EGFR-mutation positive NSCLC patients resistant to EGFR TKIs.

Citing Articles

Targeting P21-activated kinase suppresses proliferation and enhances chemosensitivity in T-cell lymphoblastic lymphoma.

Su N, Fang Y, Chen X, Chen X, Xia Z, Huang H Blood Sci. 2023; 5(4):249-257.

PMID: 37941919 PMC: 10629744. DOI: 10.1097/BS9.0000000000000169.

Efficacy of FRO on Acne Vulgaris Pathogenesis.

Kim J, Han H, Xu Y, Lee M, Lee H Pharmaceutics. 2023; 15(7).

PMID: 37514071 PMC: 10384752. DOI: 10.3390/pharmaceutics15071885.

Upgrade of an old drug: Auranofin in innovative cancer therapies to overcome drug resistance and to increase drug effectiveness.

Gamberi T, Chiappetta G, Fiaschi T, Modesti A, Sorbi F, Magherini F Med Res Rev. 2021; 42(3):1111-1146.

PMID: 34850406 PMC: 9299597. DOI: 10.1002/med.21872.

Mutated circulating tumor DNA as a liquid biopsy in lung cancer detection and treatment.

Filipska M, Rosell R Mol Oncol. 2021; 15(6):1667-1682.

PMID: 33969622 PMC: 8169447. DOI: 10.1002/1878-0261.12983.

The Role of p21-Activated Kinases in Cancer and Beyond: Where Are We Heading?.

Liu H, Liu K, Dong Z Front Cell Dev Biol. 2021; 9:641381.

PMID: 33796531 PMC: 8007885. DOI: 10.3389/fcell.2021.641381.

References

Regala R, Weems C, Jamieson L, Copland J, Thompson E, Fields A . Atypical protein kinase Ciota plays a critical role in human lung cancer cell growth and tumorigenicity. J Biol Chem. 2005; 280(35):31109-15. DOI: 10.1074/jbc.M505402200. View

Wu D, Wu T, Chen C, Lee H . PAK1 Is a Novel Therapeutic Target in Tyrosine Kinase Inhibitor-Resistant Lung Adenocarcinoma Activated by the PI3K/AKT Signaling Regardless of EGFR Mutation. Clin Cancer Res. 2016; 22(21):5370-5382. DOI: 10.1158/1078-0432.CCR-15-2724. View

Regala R, Weems C, Jamieson L, Khoor A, Edell E, Lohse C . Atypical protein kinase C iota is an oncogene in human non-small cell lung cancer. Cancer Res. 2005; 65(19):8905-11. DOI: 10.1158/0008-5472.CAN-05-2372. View

Deacon S, Beeser A, Fukui J, Rennefahrt U, Myers C, Chernoff J . An isoform-selective, small-molecule inhibitor targets the autoregulatory mechanism of p21-activated kinase. Chem Biol. 2008; 15(4):322-31. PMC: 4353635. DOI: 10.1016/j.chembiol.2008.03.005. View

Justilien V, Walsh M, Ali S, Thompson E, Murray N, Fields A . The PRKCI and SOX2 oncogenes are coamplified and cooperate to activate Hedgehog signaling in lung squamous cell carcinoma. Cancer Cell. 2014; 25(2):139-51. PMC: 3949484. DOI: 10.1016/j.ccr.2014.01.008. View

Narayan R, Fedrigo C, Brands E, Dik R, Stalpers L, Baumert B . The allosteric AKT inhibitor MK2206 shows a synergistic interaction with chemotherapy and radiotherapy in glioblastoma spheroid cultures. BMC Cancer. 2017; 17(1):204. PMC: 5359921. DOI: 10.1186/s12885-017-3193-9. View

Karachaliou N, Chaib I, Cardona A, Berenguer J, Bracht J, Yang J . Common Co-activation of AXL and CDCP1 in EGFR-mutation-positive Non-smallcell Lung Cancer Associated With Poor Prognosis. EBioMedicine. 2018; 29:112-127. PMC: 5925453. DOI: 10.1016/j.ebiom.2018.02.001. View

Hou G, Liu P, Zhang S, Yang M, Liao J, Yang J . Elimination of stem-like cancer cell side-population by auranofin through modulation of ROS and glycolysis. Cell Death Dis. 2018; 9(2):89. PMC: 5833411. DOI: 10.1038/s41419-017-0159-4. View

Semenova G, Chernoff J . Targeting PAK1. Biochem Soc Trans. 2017; 45(1):79-88. PMC: 5973817. DOI: 10.1042/BST20160134. View

10.

Jacobsen K, Bertran-Alamillo J, Molina M, Teixido C, Karachaliou N, Pedersen M . Convergent Akt activation drives acquired EGFR inhibitor resistance in lung cancer. Nat Commun. 2017; 8(1):410. PMC: 5583255. DOI: 10.1038/s41467-017-00450-6. View

11.

Furst D . Mechanism of action, pharmacology, clinical efficacy and side effects of auranofin. An orally administered organic gold compound for the treatment of rheumatoid arthritis. Pharmacotherapy. 1983; 3(5):284-98. DOI: 10.1002/j.1875-9114.1983.tb03277.x. View

12.

Zhang Z, Lee J, Lin L, Olivas V, Au V, LaFramboise T . Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. Nat Genet. 2012; 44(8):852-60. PMC: 3408577. DOI: 10.1038/ng.2330. View

13.

Chou T . Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 2010; 70(2):440-6. DOI: 10.1158/0008-5472.CAN-09-1947. View

14.

Chaib I, Karachaliou N, Pilotto S, Servat J, Cai X, Li X . Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLC. J Natl Cancer Inst. 2017; 109(9). PMC: 5409000. DOI: 10.1093/jnci/djx014. View